Hitting the snooze button: Inducing quiescence with the FLT3 inhibitor quizartinib protects hematopoietic progenitors from chemotherapy

Hitting the snooze button: Inducing quiescence with the FLT3 inhibitor quizartinib protects hematopoietic progenitors from chemotherapy

Myelosuppression is one of the most severe and limiting side effects of chemotherapy. Our recent work outlines a strategy to prevent chemotherapy-induced myelosuppression by administering a priming dose of the FMS-Like Tyrosine kinase 3 (FLT3) inhibitor quizartinib. Furthermore, by administering seq...

Full description

Bibliographic Details
Main Authors: Samuel J. Taylor, Wallace Y. Langdon
Format: Article
Language:English
Published: Taylor & Francis Group 2017-11-01
Series:Molecular & Cellular Oncology
Subjects:
flt3
myelosuppression
quizartinib
chemotherapy
acute myeloid leukemia
hematopoietic progenitors
Online Access:http://dx.doi.org/10.1080/23723556.2017.1378156

Internet

http://dx.doi.org/10.1080/23723556.2017.1378156

Similar Items